Schizophrenia – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034

Schizophrenia Emerging Therapy

Thelansis’s “Schizophrenia Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Schizophrenia Overview

Schizophrenia, a persistent and debilitating brain disorder, is typically characterized by two sets of symptoms: positive and negative. Those with schizophrenia often experience symptoms that leave them feeling fearful and withdrawn, with their speech and behavior becoming so disorganized that they can be incomprehensible or alarming to others. The ICD-10 outlines diagnostic criteria for seven subtypes of schizophrenia, which include Paranoid, Catatonic, Postschizophrenic Depression, Simple, Hebephrenic, Undifferentiated, and Residual schizophrenia. Schizophrenic disorders are thought to have a complex origin involving genetic, environmental, and neurotransmitter pathophysiological factors. Diagnosing schizophrenia involves a psychiatric assessment since no definitive test exists for the condition. In the United States, diagnosis relies primarily on the Diagnostic and Statistical Manual (DSM-V), while in Europe, the International Classification of Diseases (ICD), 10th revision, is often used. Schizophrenia necessitates lifelong treatment, even when symptoms abate. Management includes medication and psychosocial therapy, with occasional hospitalization. Treatment is typically guided by a psychiatrist experienced in schizophrenia care.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
    • Pipeline analysis
    • Target patients for emerging therapies
    • Key companies
    • Key mechanism of actions
    • Launch date estimates, etc.
  • Clinical trial landscape analysis
    • Target patient segments
    • Trial endpoints
    • Trial design
    • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
    • Performance of key current therapies
    • Top areas of unmet needs
    • Opportunity sizing for key unmet needs
  • Target Product Profiles
    • Attributes and levels
    • Physician likelihood of prescribing
    • Expected patient shares
  • KOL insights on key emerging therapies
    • Level of awareness
    • Expected use / line of therapy
    • Extent to fulfil key unmet needs
    • KOL quotes


Read more: 
Schizophrenia – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034

Comments

Popular posts from this blog

Epidermodysplasia verruciformis (EV) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2021 To 2032

Paroxysmal Supraventricular Tachycardia (PSVT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Familial Chylomicronemia Syndrome (FCS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033